- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of herpes zoster and post-herpetic neuralgia
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 390KB)
Varicella zoster virus recombinant vaccine – March 2023
Varicella zoster virus recombinant vaccine: Injection [1 vial] & adjuvant substance diluent [0.5 mL vial]; Shingrix®
Last updated
30 June 2023